Nichols & Pratt Advisers LLP MA Has $24.81 Million Position in Novo Nordisk A/S $NVO

Nichols & Pratt Advisers LLP MA lowered its position in Novo Nordisk A/S (NYSE:NVO) by 2.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 487,625 shares of the company’s stock after selling 13,366 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.6% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 23rd biggest holding. Nichols & Pratt Advisers LLP MA’s holdings in Novo Nordisk A/S were worth $24,810,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC lifted its stake in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the last quarter. Invesco Ltd. lifted its stake in Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Novo Nordisk A/S in the second quarter valued at about $314,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial win — oral semaglutide met its main goal in 10–17 year olds with type 2 diabetes, supporting a planned U.S. launch and expanding addressable market for an oral GLP‑1 in youth. Novo Nordisk’s new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Market reaction to trial news — outlets report NVO shares rising after the pediatric oral semaglutide data, indicating investor enthusiasm for incremental product launches and revenue growth. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Positive Sentiment: Competitive edge in obesity market — early prescription data show Lilly’s new obesity treatment trailing Novo’s Wegovy, pressuring Lilly shares and reinforcing Novo’s market leadership in weight‑loss drugs. Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
• Positive Sentiment: Short interest fell sharply — short interest declined ~14.6% in April to ~17.0M shares (0.4% of float), lowering potential short‑squeeze risk and signaling reduced bearish positioning. (internal short‑interest data)
• Neutral Sentiment: Valuation/price discussion — analysts and commentators are parsing whether current pricing reflects recent share weakness and longer‑term growth prospects; this keeps the stock sensitive to further data and guidance. Is Novo Nordisk (NYSE:NVO) Pricing Reflect Its Recent Share Slump And Growth Outlook
• Negative Sentiment: Analyst target trimmed — Citigroup cut its price target (DKK 309 → DKK 275) while keeping a neutral rating, a reminder of lingering valuation concerns that could cap upside. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Recent short‑term pullbacks — coverage noted a recent session where NVO closed lower, highlighting that momentum can reverse on macro or sector weakness. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market

Novo Nordisk A/S Price Performance

Shares of NVO opened at $41.19 on Friday. The firm has a market capitalization of $183.93 billion, a PE ratio of 11.87, a PEG ratio of 9.17 and a beta of 0.73. The company’s 50-day moving average is $39.13 and its 200-day moving average is $47.73. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were given a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.